CU20220019A7 - Proteínas de fusión nkg2d - Google Patents

Proteínas de fusión nkg2d

Info

Publication number
CU20220019A7
CU20220019A7 CU2022000019A CU20220019A CU20220019A7 CU 20220019 A7 CU20220019 A7 CU 20220019A7 CU 2022000019 A CU2022000019 A CU 2022000019A CU 20220019 A CU20220019 A CU 20220019A CU 20220019 A7 CU20220019 A7 CU 20220019A7
Authority
CU
Cuba
Prior art keywords
fusion proteins
nkg2d
nkg2d fusion
treating
useful
Prior art date
Application number
CU2022000019A
Other languages
English (en)
Inventor
Hilmar Ebersbach
Philip Egger
Emilie Ramondou
Ryan Sullivan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20220019A7 publication Critical patent/CU20220019A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM

Abstract

<p>La presente invención se refiere a proteínas de fusión NKG2D, útiles para prevenir y tratar un amplio espectro de tipos de cáncer.</p>
CU2022000019A 2019-09-18 2020-09-16 Proteínas de fusión nkg2d CU20220019A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902071P 2019-09-18 2019-09-18
US201962902080P 2019-09-18 2019-09-18
PCT/IB2020/058642 WO2021053556A1 (en) 2019-09-18 2020-09-16 Nkg2d fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
CU20220019A7 true CU20220019A7 (es) 2022-10-11

Family

ID=72644517

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000019A CU20220019A7 (es) 2019-09-18 2020-09-16 Proteínas de fusión nkg2d

Country Status (18)

Country Link
US (1) US20220348632A1 (es)
EP (1) EP4031566A1 (es)
JP (1) JP2022548665A (es)
KR (1) KR20220064983A (es)
CN (1) CN114401998A (es)
AU (1) AU2020347945A1 (es)
BR (1) BR112022004475A2 (es)
CA (1) CA3152236A1 (es)
CO (1) CO2022002808A2 (es)
CR (1) CR20220107A (es)
CU (1) CU20220019A7 (es)
EC (1) ECSP22019177A (es)
IL (1) IL290715A (es)
JO (1) JOP20220068A1 (es)
MX (1) MX2022003192A (es)
PE (1) PE20221416A1 (es)
TW (1) TW202124445A (es)
WO (1) WO2021053556A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215882A1 (en) * 2022-05-05 2023-11-09 Northwestern University Methods of treating immunotherapy-associated adverse effects

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US20110045536A1 (en) 2007-12-21 2011-02-24 Novartis Ag Mammalian expression vector
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
CN102197136B (zh) 2008-08-28 2016-09-28 诺华股份有限公司 通过终止密码子连读的多肽同种型的细胞表面展示
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
RU2716977C2 (ru) 2013-07-31 2020-03-17 Новартис Аг Новые селективные векторы и способы селекции эукариотических клеток-хозяев
LT3137595T (lt) 2014-04-29 2019-06-25 Novartis Ag Naujos stuburinių ląstelės ir dominančio polipeptido rekombinantinės raiškos būdai
AU2016353231B2 (en) * 2015-11-13 2020-08-13 Dana-Farber Cancer Institute, Inc. An NKG2D-Ig fusion protein for cancer immunotherapy

Also Published As

Publication number Publication date
IL290715A (en) 2022-04-01
CR20220107A (es) 2022-04-25
PE20221416A1 (es) 2022-09-20
ECSP22019177A (es) 2022-04-29
TW202124445A (zh) 2021-07-01
KR20220064983A (ko) 2022-05-19
EP4031566A1 (en) 2022-07-27
BR112022004475A2 (pt) 2022-05-31
CA3152236A1 (en) 2021-03-25
AU2020347945A1 (en) 2022-03-31
CN114401998A (zh) 2022-04-26
JP2022548665A (ja) 2022-11-21
WO2021053556A1 (en) 2021-03-25
JOP20220068A1 (ar) 2023-01-30
CO2022002808A2 (es) 2022-04-08
US20220348632A1 (en) 2022-11-03
MX2022003192A (es) 2022-04-11

Similar Documents

Publication Publication Date Title
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MY198059A (en) Anti-ox40 antibodies and their uses
EA202092435A3 (ru) Моноклональные антитела против bcma
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
AU2018258581A8 (en) RAF-degrading conjugate compounds
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
EA202092692A1 (ru) Аналоги рапамицина и их применения
WO2019051327A3 (en) BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS
MX2019011585A (es) Anticuerpos miltiespecificos estables.
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
EA202092909A1 (ru) Новый бензодиазепин, его производные и применение
CU20220019A7 (es) Proteínas de fusión nkg2d
CR20220228A (es) Anticuerpos trem2 y usos de estos
EA202092707A1 (ru) Огнеупор, шихта для его получения, способ его получения, а также применение такого огнеупора
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
WO2018146390A8 (fr) Utilisation d&#39;un compose appartenant a la famille des diuretiques pour traiter le cancer
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
CL2021002836A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos (divisional de la solicitud n° 201900424)